Kissei

Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:^[1]

• Difelikefalin
• Fostamatinib (trade name Tavalisse)
• Linzagolix
• Mitiglinide (Glufast)
• Remogliflozin etabonate
• Silodosin (Urief)
• Tranilast (Rizaben)

ISINJP3240600001

IndustryPharmaceutical products, therapeutic and care foods

FoundedAugust 9, 1946; 79 years ago (1946-08-09)

Headquarters

Matsumoto, Nagano

,

Japan

Quick facts ISIN, Industry ...

Kissei Pharmaceutical

ISIN	JP3240600001
Industry	Pharmaceutical products, therapeutic and care foods
Founded	August 9, 1946; 79 years ago (1946-08-09)
Headquarters	Matsumoto, Nagano , Japan
Key people	Mutsuo Kanzawa (CEO)
Number of employees	1504
Website	www.kissei.co.jp/e_contents/

Close

In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China.^[2]